Skip to content

Trial Summary

A phase 3 randomised study comparing nivolumab and ipilimumab combination versus placebo in participants with localized renal cell carcinoma who underwent radical or partial nephectomy and who are at high risk of relapse

Acronym:

Checkmate 914

ACTRN/NCT /ethics:

NCT03138512

Scientific title:

A study comparing the combination of nivolumab and ipilimumab versus placebo in participants with localized renal cell carcinoma

Sponsor / Cooperative group:

Bristol-Myers Squibb

Trial & Patient Characteristics

Cancer TypeKidney
Trial TypeTreatment
PhasePhase III
Age Range18 years and older
SexBoth
Tumour Stream -
Cancer StageEarly/In Situ
Anticipated Start Date2017-07-05
Anticipated End Date2023-07-07

Participating Hospitals

HospitalLyell McEwin Hospital
Clinical Trial CoordinatorAndy Phay
Emailandy.phay@sa.gov.au
Phone08 8282 0833
Principal InvestigatorDr Christopher Hocking
Recruitment StatusRecruiting